Notice of Intent to Sole Source – CARDINAL HEALTH 414, LLC– radiopharmaceuticals
- Client
- Department of Health and Human Services
- RFP Number
- —
- Posted
- 10/16/2026
- Category
- US Federal
- Budget
- —
- NAICS
- 325412
- Set-aside
- —
- Contact
- Chris Ryssa Nix
- ryssa.nix@nih.gov
Description
AI GeneratedThe National Institutes of Health Clinical Center intends to issue a sole-source purchase order to Cardinal Health 414, LLC for FDA-approved radiopharmaceuticals. The requested scope covers radiopharmaceuticals that emit gamma, positrons, beta, and alpha radiations to support patient care by the Nuclear Medicine Division, Department of Radiology and Imaging Sciences. The agency is conducting this acquisition under FAR Part 13 Simplified Acquisition Procedures with a budget not to exceed $900,000. Because this is a notice of intent to sole source, the buyer will not issue a formal solicitation document or request quotations. Interested parties may submit comments referencing posting number NOI-OD-27-000001 to Contract Specialist Ryssa Nix via email at [email protected] by October 19, 2026, at 12:00 PM EST.
Official SAM.gov notice
- Solicitation number
- NOI-OD-27-000001
- Agency
- Department of Health and Human Services
- Buying office
- National Institutes of Health › National Institutes of Health Olao
- Notice type
- Presolicitation
- Responses due
- Oct 19, 2026, 12:00 PM ET
- Posted on SAM.gov
- Oct 13, 2026
- NAICS
- 325412 · Pharmaceutical Preparation Manufacturing
- Product/service code
- 3650
- Place of performance
- Bethesda, MD, 20892
- Contracting contact
- Chris Ryssa Nix
ryssa.nix@nih.gov
Read the official notice description
This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested. This procurement is for a purchase order NTE $900,000 for FDA-approved radiopharmaceuticals for patient care by the Nuclear Medicine Division, Department of Radiology and Imaging Sciences at the NIH Clinical Center. CARDINAL HEALTH is a reputed and reliable FDA and US NRC vetted supplier of the required radiopharmaceuticals by the Clinical Center. Based on the past 25 years of contracting with this vendor, this vendor is the only acceptable vendor because they provide a comprehensive list of radiopharmaceuticals that uniquely meets the patient needs of the NIH Clinical Center. They are the only provider that can supply all radiopharmaceuticals that emit gamma, positrons, beta and/or alpha radiations. They also use a patented tungsten delivery system for dispensing the high energy positron radiopharmaceuticals. This system minimizes radiation exposure to the staff and the public, as well as meeting the weight standard that reduces the potential weightlifting injuries to the staff. This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 –Simplified Acquisition Procedures, Subpart 13.500 This subpart authorizes the use of simplified procedures for the acquisition of supplies and services in amounts greater than the simplified acquisition threshold but not exceeding $9 million ($15 million for acquisitions as described in 13.500(c)), including options, if the contracting officer reasonably expects, based on the nature of the supplies or services sought, and on market research, that offers will include only commercial products or commercial services. Contracting officers may use any simplified acquisition procedure in this part, subject to any specific dollar limitation applicable to the particular procedure. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. Comments to this announcement, referencing this posting number, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, to the attention of Ryssa Nix, Contract Specialist via email to [email protected] by close date. Notice Type: Notice of Intent NAICS Code: 325412 PSC Code: 3650 Posted Date: 10/13/2026 Close Date: 10/19/2026 12pm EST End User IC: Clinical Center POC Name: Ryssa Nix Email Address: [email protected]
Source: SAM.gov contract opportunities data (U.S. federal public data).
Incumbent
No incumbent history found for this requirement. The notice does not cite a current contract, and no earlier award from this buying office matches it.
Market context
Awards in the same category (Pharmaceutical Preparation Manufacturing). This is not this requirement's award history.
Recent similar awards: Department of Health and Human Services, NAICS 325412, performed in MD
| Vendor and award | Value | Ends |
|---|---|---|
| GE PRECISION HEALTHCARE LLC75N98026P01826 · EO 14398. VIVID PIONEER ULTRASOUND SYSTEM. | $205.2K | Sep 29, 2027 |
| QUVA PHARMA, INC.75N98026P00592 · OUTSOURCING PCAS AND EPIDURALS FOR PATIENTS CARE FROM QUVA PHARMA, INC. | $110.0K | May 25, 2027 |
| WE PHARMA, INC.75F40125F19010 · PHARMACEUTICAL DRUG PRODUCTS | $75,000 | Nov 13, 2026 |
| CARDINAL HEALTH 414, LLC75N90026F00001 · RADIOPHARMACEUTICAL PATIENT-READY UNIT DOSES FROM CARDINAL HEALTH 414, LLC:1109813 [26-000 | $612.5K | Sep 30, 2026 |
| AVIAN VACCINE SERVICES LLC75N93025P01123 · ANTIGENS FOR UNIVERSAL INFLUENZA VACCINE STUDIES | $118.0K | Sep 29, 2026 |
Top vendors in this category: Department of Health and Human Services, NAICS 325412, since Oct 1, 2024
568 contract awards in this NAICS over the period.
- 1. MCKESSON CORPORATION$276.7M
- 2. BAVARIAN NORDIC A/S$240.5M
- 3. EMERGENT BIOSOLUTIONS CANADA INC$232.6M
- 4. ALVOGEN, INC.$227.7M
- 5. DLA TROOP SUPPORT$170.9M
Source: USAspending.gov federal award data (U.S. federal public data). A contract is called the incumbent only when the notice or its documents cite it by number.
Verify important details
Document checkConfirm submission instructions and amendments with the issuing agency before responding.
Personalized fit score
Sign up free to see how well this opportunity fits your company — based on your saved profile.
Sign up to see your fit score